Abstract: Poloxamer 407 (P-407) is a copolymer surfactant that induces a dose-controlled dyslipidemia in both mice and rats. Human macrophages cultured with P-407 exhibit a concentration-dependent reduction in cholesterol efflux to apolipoprotein A1 (apoA1) linked to downregulation of the ATP-binding cassette transporter A1 (ABCA1). Activators of peroxisome proliferator-activated receptor gamma (PPARg), as well as PPARa, increase expression of liver X receptor alpha (LXRa) in macrophages and promote the expression of ABCA1, which, in turn, mediates cholesterol efflux to apoA1. The present study investigated whether P-407 interferes with this signaling pathway. A transactivation assay was used to evaluate whether P-407 can either activate or inhibit the transcriptional activity of PPARg. Because thiazolidinedione drugs (PPARg agonists) improve glycemic control in type 2 diabetes by reducing blood glucose concentrations, P-407 was also evaluated for its potential to alter plasma insulin and blood glucose concentrations in wild-type (C57BL/6) and PPARg-deficient mice. Additionally, because thiazolidinediones attenuate release of free fatty acids (FFAs) from adipocytes and, consequently, decrease circulating plasma levels of FFAs, plasma concentrations of circulating FFAs were also determined in P-407-treated mice. P-407 was unable to modulate PPARg activity in cell-based transactivation assays. Furthermore, P-407 did not perturb plasma insulin and blood glucose concentrations after administration to mice. However, by an as yet unidentified mechanism, P-407 caused a significant increase in the serum concentration of FFAs in mice beginning 3 h after administration and lasting more than 24 h postdosing. It is concluded that P-407 does not interfere with the functional activity of PPARg after administration to mice.
Introduction
The peroxisome proliferator-activated receptors PPARa and PPARg are nuclear receptors that, upon heterodimerization with the retinoid X receptor (RXR), function as ligandactivated transcriptional regulators of genes controlling lipid and glucose metabolism (Pineda et al. 1999) . PPARa, which is activated by fibrates, fatty acids, and eicosanoids (Chinetti et al. 2000) , is most highly expressed in liver, heart, muscle, and kidney, whereas PPARg 1 is expressed in many tissues and cells, including white and brown adipose tissue, skeletal muscle, intestine, and macrophages (Auwerx 1999; Gonzalez 1997; Kersten et al. 2000; Saltiel and Olefsky 1996; Spiegelman and Flier 1996) . A splice variant, PPARg 2 , is primarily expressed in both white and brown adipose tissue (Chawla et al. 1994; Kliewer et al. 1994; Tontonoz et al. 1994) . PPARg is also expressed in pancreatic b cells, but its level of expression is much lower than that found elsewhere (Braissant et al. 1996) . Agonistinduced activation of PPARg/RXR is known to increase insulin sensitivity (Lehmann et al. 1995; Mukherjee et al. 1997) . Consequently, thiazolidinedione drugs (TZDs), which are synthetic ligands of PPARg and have the ability to directly bind and activate PPARg (Lehmann et al. 1995) and stimulate adipocyte differentiation (Okuno et al. 1998; Spiegelman and Flier 1996) , are used clinically to reduce insulin resistance and improve hyperglycemia in type 2 diabetes mellitus (T2DM).
TZDs (PPARg agonists) are often used to improve hyperglycemia associated with the metabolic syndrome of T2DM. This syndrome is characterized by (i) central obesity, (ii) atherogenic dyslipidemia (that is, increased plasma triglyceride (TG) and reduced high-density lipoprotein (HDL) cholesterol), (iii) hypertension, (iv) insulin resistance or glucose intolerance, (v) a prothrombotic state, and (vi) a proinflammatory state. We have developed a chemically induced alternative animal model of hyperlipidemia and atherosclerosis by using poloxamer 407 (P-407), a copolymer surfactant, that replicates one of the features observed in the metabolic syndrome, that of atherogenic dyslipidemia (Johnston et al. 1998; Johnston 2004; Palmer et al. 1997) . Recently, we demonstrated that P-407 downregulates the gene expression of ATP-binding cassette transporter A1 (ABCA1) and inhibits cholesterol efflux from human macrophages in response to apolipoprotein A1 (apoA1) in cell culture . Hence, we wondered whether P-407, either directly or indirectly, modulates the functional activity of PPARg in the PPAR -liver X receptor (LXR) -ABCA1 signaling pathway. This would have important consequence with regard to cellular cholesterol homeostasis in this particular mouse model of atherogenesis (Johnston et al. 1998; Johnston 2004; Palmer et al. 1997) because TZDs are used, in part, to promote cholesterol efflux from macrophages in patients with T2DM.
The present work was conducted to further understand the pharmacologic effects of P-407 in our animal model of atherogenesis. Because P-407, or some intermediate that may potentially be activated in a biochemical or metabolic cascade after P-407 administration, could conceivably function as either a PPARg agonist (similar to TZDs) or a PPARg antagonist, we first used an in vitro transactivation assay to determine whether P-407 directly modulated PPARg transcriptional activity. Next, since PPARg agonists are used to treat hyperglycemia associated with T2DM, we determined whether blood glucose and plasma insulin levels were perturbed in wild-type and PPARg-deficient mice after P-407 administration. Last, we explored the possibility that P-407 acts through PPARg to effect the mobilization of free (nonesterified) fatty acids (FFAs) from adipocytes.
Our desire to investigate the possibility that P-407 acts via PPARg to cause the release of FFAs from adipocytes, thereby increasing the concentration of circulating FFAs, is based on the following information. PPARg is activated by prostaglandins, leukotrienes, and TZDs and affects the expression of many genes involved in the storage of FFAs. If P-407, or some intermediate involved in a biochemical or metabolic cascade downstream of P-407 administration, functioned as a PPARg agonist or antagonist, then the expression of genes involved in the storage of FFAs may be modulated. This potential pharmacologic action of P-407 is based on 2 previous observations. First, Wasan et al. (2003) demonstrated a significant increase in the activity of lecithin cholesterol acyltransferase (LCAT) in the plasma of P-407-treated rats relative to controls. LCAT catalyzes the formation of cholesteryl esters from lecithin (phosphatidylcholine) and cholesterol. Second, Nash et al. (1996) observed a significant decrease in the plasma concentrations of both TG and total cholesterol when nicotinic acid and P-407 were simultaneously administered to rats. Nash et al. suggested that P-407 may cause hyperlipidemia in rodents, in part, by stimulating the release of FFAs from the adipocyte for at least 24 h after its administration, although the authors did not measure circulating FFA levels in P-407-treated animals. Nicotinic acid is an effective hypolipidemic agent that functions primarily by reducing lipolysis in adipocytes, resulting in a reduction in the plasma concentration of FFAs, an essential substrate for both TG and cholesterol biosynthesis. The findings of Wasan et al. (2003) and Nash et al. (1996) suggest that P-407 may influence, either directly or indirectly, the mobilization and storage of FFAs by modulating the functional activity and (or) gene expression of PPARg. Therefore, we determined whether P-407 treatment affected the concentration of circulating FFAs in wild-type mice.
Materials and methods

Materials
Plasmids were obtained from the same sources as previously reported (Maloney and Waxman 1999; Shipley and Waxman 2004; . Troglitazone (Rezulin), a potent PPARg agonist, was obtained from Parke-Davis Pharmaceuticals (Ann Arbor, Mich.). Male wild-type mice (strain C57BL/6) and PPARg-deficient mice (strain B6.129-Pparg tm2Rev /J) were purchased from The Jackson Laboratory (Bar Harbor, Me.) and weighed approximately 18 g. Test strips, which were inserted into the test strip chamber of the blood glucose monitor, were Chemstrip bG reagent strips (No. 502, Boehringer Mannheim, Indianapolis, Ind.). For determination of plasma insulin concentrations, commercially available Coat-A-Count radioimmunoassay kits were obtained from Diagnostic Products (Los Angeles, Calif.). An in vitro enzymatic, colorimetric assay kit (NEFA-C) for the determination of serum FFAs was purchased from Wako Diagnostics (Richmond, Va.).
Transactivation assay
The transactivation assay described previously (Maloney and Waxman 1999; ) was used to assess the effect of P-407 on PPARg activity. Briefly, COS-1 cells (American Type Culture Collection, Rockville, Md.) were passaged in 100-millimetre tissue culture dishes (Greiner Labortechnik, Germany) in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, N.Y.) and 50 U/mL penicillin-streptomycin (Gibco). Cells were cultured overnight at 37 8C and then reseeded at 2000-4000 cells/well in a 96-well tissue culture plate (Greiner Labortechnik) in DMEM containing 10% FBS. The cells were grown for 24 h and then transfected as described previously (Chang and Waxman 2005; Maloney and Waxman 1999 ) by using FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, Ind.), which provides higher transfection efficiencies and more consistent results when compared with calcium phosphate transfection methods.
Twenty-four hours after drug treatment (P-407 or 3.0 mmol/L troglitazone), cells were washed once in cold phosphate-buffered saline (pH 7.4) and then lysed by incubation at 4 8C in passive cell lysis buffer for 15-30 min (Promega). Firefly and Renilla luciferase activities were measured in the cell lysate by using the dual luciferase activity kit (Promega).
In vivo experiments
To determine whether PPARg was involved with any potential changes in plasma insulin and blood glucose concentrations after administration of P-407, we used 4 groups of mice. Groups 1 and 2 consisted of wild-type mice treated with saline or P-407 (0.5 g/kg), respectively. Groups 3 and 4 were PPARg-deficient mice administered either saline or P-407 (0.5 g/kg), respectively. It should be noted that disruption of the gene for PPARg does not cause any significant changes in blood insulin and glucose concentrations relative to these parameters in controls (He et al. 2003) . All procedures for P-407 administration and subsequent blood collection were in accordance with the guide for the care and use of laboratory animals of the University of Missouri -Kansas City, and the treatment protocol was approved by the institutional animal care and use committee.
To determine whether P-407 caused any change in the concentrations of plasma insulin and blood glucose in normal mice, as well as whether any potential changes to the concentrations of plasma insulin and blood glucose were mediated through PPARg, 12 wild-type mice and 12 PPARg-deficient mice were randomly divided into the same 4 groups. All mice were administered 0.5 mL of either normal saline (groups 1 and 3) or P-407 (0.5 g/kg) (groups 2 and 4) by intraperitoneal injection. Blood samples were obtained from all mice by tail vein sampling at 0 h (before P-407 administration), and then at 2, 4, 8, 16, and 24 h postdosing. Fifty microlitres of blood was collected into heparinized tubes at each sampling time point. One drop was immediately used for determination of blood glucose, while the remainder of the blood sample (approximately 40 mL) was centrifuged, the plasma obtained, and the plasma samples stored at -80 8C until the time of insulin analysis.
The concentration of glucose in each blood sample was determined by using a commercially available blood glucose monitor (model 792 Accu-Chek II, Boehringer Mannheim, Indianapolis, Ind.). One drop of blood was placed on a glucose reagent strip, which was allowed to stand at room temperature for 1 min before being inserted into the test strip chamber of the monitor for determination of blood glucose, measured in milligrams per decilitre (mg/dL). Blood glucose concentrations were then expressed in units of millimoles per litre (mmol/L).
The concentration of insulin in all plasma samples was determined by using a radioimmunoassay kit according to the manufacturer's instructions. In the plasma insulin determination procedure, [ 125 I]insulin competes with insulin in the plasma sample for sites on insulin-specific antibody immobilized to the wall of the polypropylene tube. After incubation, isolation of the antibody-bound fraction was achieved by simply decanting the supernatant. The tube was then counted in a model LS 6500 Beckman liquid scintillation counter (Fullerton, Calif.), the counts being inversely related to the amount of insulin present in the plasma sample. The quantity of insulin in the sample was then determined by comparing the counts with a standard curve (package insert M-097, 5 September 1991, Diagnostic Products, Los Angeles, Calif.). Finally, the plasma insulin concentrations were calculated and expressed in picomoles per litre (pmol/L).
Analysis of serum free fatty acids
An additional group of 6 wild-type mice were utilized to determine whether P-407 caused a change in the circulating levels of FFAs in the serum. In these experiments, the mice were fasted for 12 h before the experiment. On the day of the experiment, 50 mL of blood was collected from the tail vein of each mouse and served as the preinjection (time t = 0 h) control (baseline) FFA concentration for each mouse. Next, 0.5 mL of P-407 (0.5 g/kg) was administered by intraperitoneal injection to each mouse and blood samples (50 mL) collected from the tail vein of each fasting mouse at 3, 6, 12, and 24 h postdosing. To determine whether fasting influenced the serum levels of FFAs, another group of 6 wild-type mice were similarly fasted, then injected with normal saline (0.5 mL) at t = 0 h, and blood samples were obtained at the same time points as those of mice treated with P-407. All blood samples were placed into microcentrifuge tubes on ice and allowed to clot. Blood samples were then centrifuged at 10 000g for 20 min at 4 8C and the serum supernatant removed and frozen at -80 8C until the time of FFA analysis.
Analysis of serum samples for FFA utilized a procedure, adapted for a 96-well microtiter plate, supplied by the manufacturer. Briefly, an aliquot (5 mL) of each serum sample was placed into a separate well and 100 mL of color reagent A added to each well. Next, samples were mixed and incubated at 37 8C for 5 min, after which time, 200 mL of color reagent B was added to each well. The plate was again incubated at 37 8C for 5 min, removed from the incubator, and 5 min later, the plate read at 550 nm using a model 450 microplate reader (Bio-Rad, Richmond, Calif.). Both a reagent blank and a calibration standard, as well as a specimen blank (to correct for lipemic samples), were included in the assay.
Data analysis
To determine whether P-407 modulated mouse and human PPARg in the transactivation assays, we utilized a classic one-way analysis of variance (ANOVA) to uncover any significant differences in the mean values associated with the individual P-407 concentrations tested relative to the vehicle (Fig. 1) . ANOVA was also utilized to determine whether increasing concentrations of P-407 inhibited troglitazone's capacity to activate human PPARg (Fig. 2) . Last, similar to the treatment of the data obtained from the transactivation assays, ANOVA was used to compare the plasma insulin and blood glucose concentration versus time profiles. Using the blood glucose concentration versus time profiles (Fig. 3a) as an example, we determined whether each blood glucose concentration at a given time point was different from the rest of the blood glucose concentrations at that same time point between the 4 groups of mice. This statistical analysis was performed for the 4 blood glucose concentrations at each of the 5 sampling time points and any significant (p < 0.05) differences between the 4 concentrations at a specific time point were appropriately designated on the resulting graph. Plasma insulin concentration versus time profiles (Fig. 3b) were analyzed in a similar manner.
Data obtained from the analysis of serum FFAs were first corrected by using the reagent and specimen blanks as per the manufacturer's instructions. The resulting mean value of the serum FFA concentration at each time point for P-407-treated mice was then individually compared with the mean serum FFA concentration at t = 0 h (that is, the preinjection level of 0.83 mEq/L) by using the Student's t test, results being deemed statistically significant if p < 0.05. Additionally, the mean value of the serum FFA concentration at each time point for P-407-treated mice was compared with the corresponding mean serum FFA concentration for salinetreated mice by using the Student's t test and deemed significantly different if p < 0.05.
Results
Transactivation assay
As determined in a cell-based transactivation assay, P-407 did not directly modulate the activity of either mouse or human PPARg relative to vehicle (Figs. 1a and 1b, respectively) . Additionally, Fig. 2 demonstrates that P-407, over a concentration range of 0.05-200 mmol/L, did not inhibit a known PPARg agonist (troglitazone) from activating human PPARg. 
PPARg-deficient mouse experiments
These experiments were designed to assess whether P-407 indirectly modulated PPARg activity and thereby altered plasma insulin and blood glucose concentrations. As shown in Fig. 3a , blood glucose concentration-time profiles for both wild-type and PPARg-deficient mice treated with P-407 were no different than corresponding profiles obtained when mice were treated with saline. The concentration-time profiles were overlapping and grouped around an average blood glucose concentration of approximately 8.5 mmol/L. Similar to the blood glucose results, plasma insulin concentration-time profiles were also overlapping and appeared to be grouped around an average plasma insulin concentration of approximately 328 pmol/L (Fig. 3b) . No significant differences were noted for concentration-time profiles in Figs. 3a and 3b when analyzed using an ANOVA.
Serum FFA concentrations
Administration of P-407 to wild-type mice caused a significant (p < 0.05) increase in the serum concentration of FFAs as soon as 3 h after injection when compared with corresponding FFA concentrations in saline-treated controls (Fig. 4) . The serum FFAs appeared to reach an apparent maximal concentration of 1.61 mEq/L at 12 h after P-407 administration, FFA concentrations remaining significantly elevated for as long as 24 h postdosing. The baseline (preinjection) FFA concentration in fasted wild-type mice administered P-407 was 0.83 mEq/L, not significantly different from the average serum FFA concentration in saline-treated mice (approximately 0.87 mEq/L).
Discussion
The present study demonstrated that P-407 does not directly activate either mouse or human PPARg in vitro. Moreover, as assessed by a transactivation assay, P-407 does not inhibit the capacity of the known PPARg agonist troglitazone to activate human PPARg. These observations suggest that our previous finding of reduced cholesterol efflux by macrophages cultured with P-407 is a result of downregulation in the gene expression of ABCA1 as proposed , and not the result of interference with the functional activity of PPARg. Additionally, it should be noted that we recently demonstrated with a transactivation assay that P-407 neither modulated PPARa activity in vitro, nor altered the plasma concentrations of total cholesterol, HDL-cholesterol, non-HDL-cholesterol, or triglycerides in PPARa-deficient mice relative to P-407-treated wild-type mice (Johnston and Waxman 2008) .
The second portion of this study focused on whether P-407 perturbed plasma insulin and blood glucose concentrations in mice and, if so, whether this outcome was mediated through PPARg. Although the transactivation assays demonstrated that P-407 was unable to activate mouse or human PPARg activity in vitro, we still wished to know whether P-407 indirectly modulated PPARg in vivo. This concern was based on the fact that a compound's ability to modulate PPARs is not always predicted from the results of an in vitro transactivation assay. For example, Peters et al. (1996) demonstrated that dehydroepiandrosterone-3-betasulfate (DHEA-S) does not modulate PPARa in vitro as assessed by a transactivation assay, yet in studies using PPARa-knockout mice, PPARa was obligatory for DHEA-S-stimulated hepatic peroxisomal gene induction.
When we initiated the present study, we had no a priori knowledge whether the administration of P-407 to wild-type mice would cause any changes in the plasma insulin and blood glucose concentrations. Our data suggest that P-407 has no capacity to modulate either plasma insulin or blood glucose concentrations after administration to wild-type mice. To assess whether any potential P-407-induced changes in insulin and glucose concentrations were mediated through PPARg, we also included a group of P-407-treated PPARg-deficient mice and determined the plasma insulin and blood glucose concentrations versus time postdosing. Our findings revealed no P-407-mediated perturbations in the plasma insulin and blood glucose concentration-time profiles for P-407-treated PPARg-deficient mice when compared with P-407-treated wild-type mice. This was also true when the profiles were individually compared with the corresponding profiles for saline-treated PPARg-deficient and saline-treated wild-type mice. Therefore, this strongly suggests that P-407 has no indirect capacity to activate or inhibit PPARg, and thus corroborates our in vitro data obtained from the transactivation assays. As an example, if P-407 had acted as a PPARg agonist similar to TZDs, then blood glucose concentrations would have been significantly reduced after the administration of P-407, but this outcome did not occur in the present study.
In accordance with the idea that PPARg ligands elicit their effects primarily through adipose tissue, it has been demonstrated that PPARg agonists alter the expression of genes that are involved in lipid uptake, lipid metabolism, and insulin action in adipocytes (Rangwala and Lazar 2004) . As a result, they enhance adipocyte insulin signaling, lipid uptake, and anabolic lipid metabolism and also attenuate lipolysis and FFA release. Consequently, lipid levels in adipose tissue increase, whereas the concentration of circulating FFAs decrease (Bays et al. 2004) . By repartitioning lipids away from liver and muscle, the 2 primary tissues that are responsible for insulin-mediated glucose disposal and metabolism, PPARg agonists improve glycemic control by reversing lipotoxicity-induced insulin resistance (Berger et al. 2005) . Because of these multiple adipocentric actions, PPARg agonists (for example, TZDs) decrease blood glucose concentrations. As shown in the present study, P-407 did not affect either the plasma insulin or blood glucose concentrations after administration to wild-type or PPARgdeficient mice. Therefore, P-407 is neither functioning as a PPARg agonist, nor does it appear to be functioning as a PPARg antagonist, since P-407 was not able to block the action of the PPARg agonist troglitazone from activating PPARg in the transactivation assays.
Finally, as stated earlier, PPARg agonists cause a reduction in the circulating levels of FFAs. In the present investigation, we demonstrated that P-407 increased the level of FFAs in the serum for up to 24 h postdosing. Because P-407 causes a decrease in cellular cholesterol efflux , which is opposite to the action of both PPARa and PPARg agonists (Chawla et al. 2001; Chinetti et al. 2001) , perhaps cholesterol homeostasis is maintained, in part, by a P-407-mediated release of FFAs (an essential substrate for both TG and cholesterol synthesis) from adipocytes, as well as by an increase in cholesterol synthesis due to a temporary (up to 48 h after P-407 administration) upregulation in the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase Leon et al. 2006) . Future work will examine potential mechanisms responsible for the elevation of serum FFAs after P-407 administration to mice.
In conclusion, P-407 neither activated nor inhibited PPARg in vitro, nor did it interfere with activation of human PPARg by a known PPARg agonist (troglitazone). Furthermore, after administration to both wild-type and PPARg-deficient mice, P-407 did not perturb plasma insulin and blood glucose concentrations, suggesting that P-407 does not indirectly activate or inhibit PPARg activity in vivo. Last, in contrast to a PPARg agonist, P-407 administration to mice increased the concentration of circulating FFAs by an as yet undetermined mechanism, but one that is probably unrelated to the inhibition of PPARg activity. Therefore, because our previous work has shown that (i) P-407 does not interfere with an LXRa agonist's ability to enhance cholesterol efflux from human macrophages , and (ii) ABCA1 gene expression is significantly reduced by P-407 , and because our present work has demonstrated that P-407 is unable to activate or inhibit PPARg in vitro or to perturb plasma insulin and blood glucose levels after administration to mice, we conclude that (i) P-407 does not modulate cellular cholesterol efflux at the level of PPARg in the PPAR-LXR-ABCA1 signaling pathway, and (ii) although P-407 increases the level of FFAs in the serum for up to 24 h postdosing, it does not interfere with the functional activity of PPARg after administration to mice.
